The value of ctDNA in predicting postoperative recurrence of non-small cell lung cancer: a meta-analysis and systematic review

Abstract Objective: Lung cancer is the most common malignant tumor worldwide, and non-small cell lung cancer(NSCLC) accounts for approximately 85% of all lung carcinoma cases. Despite surgical operation is still the primary method for treating early NSCLC, there are still a considerable postoperative recurrence patients even after complete resection. Currently, circulating tumor DNA(ctDNA) is being recognised as a molecular biomarker of minimal residual disease(MRD) in predicting postoperative recurrence of NSCLC in clinical trials and has not been confirmed. The goal of our study is to evaluate the value of ctDNA in predicting postoperative recurrence in NSCLC patients.Method: A comprehensive systematic literature research was performed for studies exploring the value of ctDNA in predicting postoperative recurrence in NSCLC patients up to February 2022. The eligible studies were collected, and the dependent variable analysis was performed to compare the relative risk (RR) of recurrence in the postoperative ctDNA positive and negative groups. The relative ratio (RR) and 95 % confidence interval (CI) were determined as comparative measures of postoperative recurrence-free survival (RFS). Ten researches comprising 799 patients, published between 2017 and February 2022, were finally enrolled into our meta-analysis.Result: A total of 10 studies including 799 patients were summarized for meta-analysis of ctDNA in predicting recurrence in NSCLC. The combined RR was 3.75 ( 95 % CI : 1.98-4.72, P < 0.05 ), which indicated that patients with postoperative ctDNA positive had a higher postoperative recurrence rate in NSCLC than postoperative ctDNA negative. In addition, Meta-analysis of 4 studies with available data showed that preoperative peripheral blood ctDNA positive showed poor prognosis of RFS with combined HR = 3.40(95%CI: 2.72-4.69, P < 0.05).Conclusion: For NSCLC patients, ctDNA is a promising biomarker for predicting postoperative recurrence, which can be used as a supplement to the current monitoring of radiation and blood biomarkers to better guide the treatment selection and prognosis of patients after surgery..

Medienart:	Preprint

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	ResearchSquare.com - (2023) vom: 04. Dez. Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Beteiligte Personen:	Li, Yifan [VerfasserIn] Yin, Qifan [VerfasserIn] Qie, Peng [VerfasserIn] Han, Shaohui [VerfasserIn] Li, Xiaoning [VerfasserIn] Zhou, Shaohui [VerfasserIn] Zhang, Guibin [VerfasserIn] Wang, Huien [VerfasserIn]

Links:	Volltext [kostenfrei]

Themen:	570 Biology

doi:	10.21203/rs.3.rs-1635255/v1

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	XRA035989262